Canadian grants & funding programs

Honey Bee Health Initiative

50% funding for hive health, pest management, equipment upgrades, and new bee stock.

The program provides 50% cost-share funding for operational improvements and equipment purchase, with a maximum of $25,000 for registered commercial beekeepers and $4,500 for registered hobbyist beekeepers.

Ontario

StandWithOwners

50% funding for technology, marketing, and community initiatives to elevate your business.

The Canada Small Business Financing Program (CSBFP) is a government-sponsored loan program administered by the Business Development Bank of Canada (BDC) that provides financial assistance to small businesses in Canada to help them obtain financing for the purchase or improvement of fixed assets.

Canada

Mechanisms and Targets at the Intersection of HIV and Substance Use (R01 Clinical Trials Not Allowed)

The purpose of this FOA is to support basic research on signaling pathways and mechanisms including HIV-host protein interactions and post-translational modifications by which addictive drugs and HIV infection converge to induce changes in brain function and cause neuropathological alterations and neurocognitive dysfunctions. This FOA also aims to promote discovery and development of novel chemical and biological approaches for prevention or mitigation of CNS complications associated with HIV infection and substance use disorders.

United States

Postbaccalaureate Research Education Program in Diabetes, Endocrinology and Metabolic Diseases (R25 Independent Clinical Trial not Allowed)

This Funding Opportunity Announcement (FOA) provides support to eligible, domestic institutions to develop and implement Postbaccalaureate Research Education Programs in Diabetes, Endocrinology and Metabolic Diseases (DDEMD). These post-baccalaureate research programs will incorporate extensive research experiences and well-designed courses for skills development to prepare recent college graduates from diverse backgrounds to transition into and complete rigorous, research-focused biomedical doctoral degree programs (e.g., Ph.D. or M.D./Ph.D.). The long-term goal of post-baccalaureate participants admitted to the program should be pursuing a career focused on DDEMD-related research. Eligible applicants for the R25 must be research-intensive doctoral degree-granting institutions with a research base in DDEMD science of at least $3 million in direct costs of peer-reviewed research projects, and research opportunities for students admitted to the program must be in DDEMD science.

United States

Development and Validation of Models for Alzheimers Disease-Related Dementias (ADRD) (R61/R33 - Clinical Trial Not Allowed)

"This FOA would support development and validation of clinically relevant models of AD/ADRD including post-TBI dementias. Models could include small animals, larger animals, ex vivo models, human iPSCs, or other in vitro models. Validation includes internal, face, construct, and predictive (to the extent possible) validation. Such validations could include looking at underlying mechanism/pathways, functional imaging, behavior, and other cognitive readouts. Independent replication is also encouraged. . These models can be developed/validated with the goal of supporting therapy development or better understanding of human disease mechanisms and mechanisms that uncover predisposition to developing neurodegenerative dementias. Either way, it is essential that models reflect the human condition as much as possible. Novel models of complex pathology or comorbid conditions are encouraged. Such models could include multiple manipulations (genetics, environment, lifestyle, age, etc.) to better reflect the complex interaction of risk factors in patients. New models need to be innovative and address a gap in the currently available models."

United States

Catalyze: Product Definition for Small Molecules and Biologics - Preliminary Product/Lead Series Identification (R33 - Clinical Trial Not Allowed)

This Funding Opportunity Announcement (FOA) will provide the early stage translational support needed to identify a lead compound series toward development of potential therapeutic agents to treat heart, lung, blood, and sleep diseases and disorders. This FOA is part of a suite of Catalyze innovation grants to advance projects to the point where they can meet the entry criteria for the NHLBI Catalyze Preclinical program or attract independent development support from other federal or private partners for preclinical optimization and development of therapeutic agents.

United States

Leveraging Big Data Science to Elucidate the Mechanisms of HIV Activity and Interaction with Substance Use Disorder (R01 Clinical Trials Not Allowed)

The purpose of this FOA is to attract data and computational scientists to propose novel ways to integrate data of different types and scales to allow new types of analysis. It is expected that with the development and application of novel computational, bioinformatics, statistical, and analytical approaches, previously inaccessible insights will reveal new aspects of addiction biology.

United States

Catalyst Award for Early-Stage Investigators (ESIs) Pursuing Research on HIV Comorbidities, Coinfections, and Complications (DP1- Clinical Trial Optional)

This Funding Opportunity Announcement (FOA) supports research from creative early stage investigators who propose highly innovative, pioneering studies with potential to open new areas of HIV/AIDS related to coinfections, comorbidities, and complications. Projects should reflect new and novel scientific directions that are distinct from concepts and approaches being pursued in the investigators research program or elsewhere. Projects must be consistent the scientific priorities outlined by the NIH Office of AIDS Research (OAR). These priorities have been most recently been described in NOT-OD-20-018.

United States

NCCIH Natural Product Early Phase Clinical Trial Phased Innovation Award (R61/R33 Clinical Trial Required)

This Funding Opportunity Announcement (FOA) encourages applications for investigator-initiated, early phase, clinical trials of natural products (i.e., botanicals, dietary supplements, and probiotics), which have a strong scientific premise to justify further clinical testing. Under this FOA, trials must be designed so that results, whether positive or negative, will provide information of high scientific utility and will support decisions about further development or testing of the natural product. This FOA will provide up to two years (R61 phase) of support for milestone-driven testing of bioavailability, pharmacokinetics, and assessment of the natural products effect (i.e., measure of mechanism of action) when used by humans on a biological signature(s). If milestones in the R61 phase are achieved, up to 3 years of additional support (R33 phase) may be awarded to replicate the impact of the natural product on the biological signature(s) when used by humans and assess whether there is an association between the degree of the impact on the biological signature and functional or clinical outcomes in a patient population. Applications can design R33 studies to determine how to optimize the impact of the natural product on the biological signature by (1) optimizing the delivery of the natural product by dose or formulation; (2) combining the natural product with another treatment approach that is known to impact the same biological signature; or (3) studying the impact of the natural product in a target population that is more responsive. Clinical trials submitted under this FOA are expected to be hypothesis based, milestone-driven, and directly related to the research priorities and mission of NCCIH. This R61/R33 funding mechanism is intended to accelerate the translation of emerging basic science findings about natural products into early-stage clinical testing to determine whether continued clinical research is warranted. This FOA will not support efficacy or e

United States

CCRP Initiative: Countermeasures Against Chemical Threats (CounterACT) Therapeutics Discovery and Early-Stage Development (UG3/UH3 Clinical Trial Not Allowed)

This Funding Opportunity Announcement (FOA) solicits applications for the early-stage development of therapeutics to mitigate the adverse health effects resulting from toxic chemical exposure. Chemical threats are toxic compounds that could be used in a terrorist attack or accidentally released from industrial production, storage or shipping. They include specific chemical warfare agents, toxic industrial chemicals, pesticides, and pharmaceutical-based agents. The overall scope of this solicitation includes validation of therapeutic targets and preclinical characterization of lead compounds. The UG3 phase of this FOA supports target validation and characterization of initial lead compound(s); UH3 phase activities include candidate optimization and in vivo demonstration of activity and efficacy in relevant post-exposure models. At the conclusion of the overall UG3/UH3 funding period, projects are expected to deliver at least one well-characterized therapeutic candidate.

United States

Patient Engagement Resource Centers to Inform SUD Treatment Services Research (R24 Clinical Trial Optional)

Only 1 in 10 people who need SUD treatment ever receive it. National survey data indicate that this treatment gap is largely driven by a misalignment between how treatment is designed (location, duration, structure, cost) and how patients prefer to engage in services. This FOA will support Patient Engagement Resource Centers to incorporate the perspectives of patients (including prospective patients, affected families, and persons in recovery) into research to inform the design and delivery of high quality treatment services that are responsive to their needs and preferences.

United States

Electricity Management Systems

50% funding for energy management systems, diagnostics, and implementation. Drive efficiency today.

The Electricity Management Systems Program provides financial assistance to cover up to 50% of the costs to purchase and install diagnostic equipment, or to implement an electricity management system (EMS) or an energy management information system (EMIS) for businesses in Quebec.

Quebec

Electricity Management Systems Program

50% funding for energy management systems, diagnostics, and implementation. Drive efficiency today.

Program providing 50% financial assistance up to $175,000 for adopting electricity management systems in industrial facilities in Quebec.

Quebec

Ending the HIV Epidemic: Resource Center to Engage Justice-Involved Populations (U24 Clinical Trial Optional)

The goal of this initiative is to develop a patient-focused research resource center to support the work of the HIV/Justice Regional Research Hubs described in RFA-DA-24-105. The project will create a Patient Engagement Resource Center (PERC) that will partner with patients and others having lived experience with HIV, SUD, and the criminal legal system to form a research advisory/consultation model that can support the Regional Research Hub projects. In addition, the awardee will conduct original research to identify key access and utilization barriers to HIV/SUD services for individuals with criminal-legal involvement; and pilot test potential solutions. The overarching goal is to embrace user-centered design principles to inform both research and practice, in order to better engage populations involved in the criminal legal system in HIV and SUD prevention and treatment.

United States

Theatrical documentary program – Indigenous stream

75% funding for production, post-production, and audience engagement of your documentary.

The Theatrical Documentary Program offers funding for feature-length documentary projects in production and post-production. Canadian audiovisual production companies that meet the eligibility criteria may apply.

Canada

Theatrical documentary program

75% funding for production, post-production, and marketing of your documentary project.

The Theatrical Documentary Program finances feature-length documentary projects in production and post-production.

Canada

Limited Competition: Molecular Transducers of Physical Activity Chemical Analysis Sites (U24 Clinical Trial Not Allowed)

The purpose of this FOA is to invite applications for Chemical Analysis Sites to serve as part of the Molecular Transducers of Physical Activity Consortium (MoTrPAC; http://commonfund.nih.gov/MolecularTransducers). This is a limited competition FOA and open only to the previously funded grantees of MoTrPAC Chemical Analysis sites through RFA-RM-15-010 and RFA-RM-15-011. Awards made through this FOA will support participation of grantees in the MoTrPAC consortium activities and the continuation of the analysis of tissues collected by the MoTrPAC consortium. Awardees will conduct omics analysis of tissues collected from human participants undergoing a physical activity intervention, generate well curated datasets, contribute that data to a public consortium database, and participate in the data analysis to generate molecular fingerprints of candidate transducers of physical activity.

United States

Canadian International Innovation Program (CIIP) - Partnership Development Activities

The Canadian International Innovation Program (CIIP) supports collaborative research and development projects that lead to commercialization of new products, services, or processes. CIIP seeks to match Canadian businesses with international partners in Brazil, China, India, Israel, and South Korea to achieve synergistic benefits.

Canada

Understanding Chronic Conditions Understudied Among Women (R01 Clinical Trial Optional)

The purpose of this Funding Opportunity Announcement (FOA) is to invite R01 applications on chronic conditions understudied among women and/or that disproportionately affect populations of women who are understudied, underrepresented, and underreported in biomedical Research should align with Goal 1 of the 2019-2023 Trans-NIH Strategic Plan for Women's Health Research "Advancing Science for the Health of Women." The awards under this FOA will be administered by NIH ICs using funds that have been made available through the Office of Research on Womens Health (ORWH) and the scientific partnering Institutes and Centers across NIH.

United States

BJA FY 23 Visiting Fellows Program

OJP is committed to advancing work that promotes civil rights and racial equity, increases access to justice, supports crime victims and individuals impacted by the justice system, strengthens community safety and protects the public from crime and evolving threats, and builds trust between law enforcement and the community.. . This solicitation will prioritize people with lived experience who bring knowledge and critical perspectives to help BJA reach and resonate with those impacted by the criminal justice system.. . With this solicitation, BJA seeks to invest in current and future leaders in the criminal justice field to advance priority national policy issues and offer cross-developmental opportunities for DOJ staff and criminal justice practitioners and researchers. Awards made under the BJA Visiting Fellows Program will fund fellowships for a period of 24 months, including a "residency" period of 9 to 12 months when the fellow will be expected to commit a significant portion of their time to the fellowship and have an opportunity to work closely with BJA staff members both virtually and with some portion of their time working onsite at BJA in Washington, D.C. . . The purpose of each fellowship is to make important policy and programmatic contributions in a criminal justice focus area. Fellows will collaborate with BJA and DOJ staff members to provide critical outreach, data, research, and subject matter expertise to inform the development of new BJA strategies, policies, and programs to benefit the field.

United States

The Intersection of Sex and Gender Influences on Health and Disease (R01 Clinical Trial Optional)

The purpose of this Funding Opportunity Announcement (FOA) is to invite R01 applications on the influence and intersection of sex and gender in health and disease including: (1) research applications that examine sex and gender factors and their intersection in understanding health and disease; and (2) research that addresses one of the five objectives from Strategic Goal 1 of the new 2019-2023 Trans-NIH Strategic Plan for Women's Health Research" Advancing Science for the Health of Women." The awards under this FOA will be administered by NIH ICs using funds that have been made available through the Office of Research on Womens Health (ORWH) and the scientific partnering Institutes and Centers across NIH.

United States

F23AS00037 Research and Development of Biotechnological Tools for White-nose Syndrome

The U.S. Fish and Wildlife Service (Service) is making funding available in 2022 and 2023 for research and development of enduring solutions to manage white-nose syndrome (WNS) in bats. The Service provides financial and technical assistance to nongovernmental, university, and private researchers, as well as state and local governments, Native American tribes, and federal agencies, for the management of WNS and conservation of bats. Projects supported under this funding opportunity will investigate, develop, evaluate, and implement innovative biotechnologies to eliminate the threat of WNS to bats in North America. . . Since 2007, white-nose syndrome has caused the deaths of millions of bats in North America. The disease is caused by an invasive fungus, Pseudogymnoascus destructans (Pd), in the Phylum Ascomycota, that grows best in cold, damp, dark environments like those preferred by hibernating bats. Twelve species of bats in temperate North America are known to be susceptible to infections by Pd, but the severity of WNS varies considerably among them.  Several species suffer high rates of mortality from WNS while others suffer only minor infections. An additional six North American bat species are known to have been exposed to Pd but have not been shown to suffer infection. In Europe and Asia, where Pd likely originated, multiple bat species are known to be susceptible to WNS, but with only minor infections and no evidence of mass mortality from the disease. As of August 2022, WNS is confirmed or suspected in bats in 39 states and eight Canadian provinces, and evidence of the causative fungus, Pd, has been detected in at least four additional states without signs of the disease. For information on WNS and previously funded projects, please see: http://www.whitenosesyndrome.org/  . . Growth in our scientific understanding of WNS, Pd, and susceptible bats has been rapid since the disease was first identified in 2007. Evidence from multiple lines of investigation, along with recent advances in biotechnology, have laid the groundwork for developing biotechnological tools that may put an end to the threat this invasive species poses to bats in North America.. . Funding through the Research and Development of Biotechnological Tools for WNS grant opportunity will advance projects that leverage knowledge about WNS, fungal pathogens, invasive species, wildlife diseases and other relevant topics to produce enduring solutions to WNS in North America. We seek management solutions that are pathogen-specific, effective, scalable, and safe for native biota and environments. For this opportunity, we consider biotechnological tools to be those that involve the modification of an organism or genome for the purposes of acting on the function of an organism (in this case, Pd). Projects submitted to this opportunity should clearly achieve progress toward an implementable management tool. Collaborations are encouraged and applicants are invited to contact a member of the Service’s WNS coordination team (below) while developing their projects. . .  . . Goal: Eliminate the threat of Pd to hibernating bats in North America. . . Objective 1: Develop biotechnological tools that remove or suppress Pd’s pathogenic properties, making it unable to cause severe disease. . . Objective 2: Develop biotechnological tools that reduce or eliminate the environmental reservoir of Pd in treated sites. 

United States

Implementation and Management of the U.S. Alumni Network of Tajikistan (USANT)

A. PROGRAM DESCRIPTION. . . . . . . The U.S. Embassy Dushanbe. . . . announces an open competition for organizations to submit applications to carry out a program to provide logistical management of a network of alumni of U.S. government (USG) programs and implement the Democracy Outreach Alumni Grant Program in Tajikistan.¬†Please follow all instructions below.. . . . . ¬†. . . . . Priority Region:¬†. . Tajikistan. . . . . ¬†. . . . . Program Background: . . . . . ¬†. . . . . The U.S. Alumni Network in Tajikistan (USANT) is a program funded by the U.S. Embassy Public Diplomacy Section in Dushanbe to provide logistical management of a network of alumni of U.S. government (USG) programs in Tajikistan.¬†USANT was created in 2019 with the goal of supporting and strengthening the USG alumni community to build upon the shared intellectual, social, cultural, and democratic values of the people of Tajikistan and the United States.. . . . . ¬†. . . . . The most significant result of the USANT project to date is creating a community among U.S. government exchange program alumni across all four regions of Tajikistan.¬†Alumni have demonstrated high interest and desire to be part of the USANT community and actively participate in network activities.. . . . . ¬†. . . . . USANT‚Äôs accomplishments over the last four years:. . . . . ¬?¬†¬†¬†¬†¬†¬†¬†Established a national organization with eight elected board members, created an active online platform, and established four regional chapters throughout Tajikistan.. . . . . ¬?¬†¬†¬†¬†¬†¬†¬†Conducted annual regional USANT conferences in each of the four chapters.. . . . . ¬?¬†¬†¬†¬†¬†¬†¬†Conducted community-based initiatives, professional trainings, webinars, and mentorship programs.. . . . . ¬?¬†¬†¬†¬†¬†¬†¬†Issued 44 USANT alumni mini grants and 16 Democracy Outreach Alumni Grants.. . . . . ¬†. . . . . PDS will develop a project handover protocol in cooperation with the current implementer and any new implementer to insure a smooth and transparent transition process.¬†. . . . . ¬†. . . . . Program Goal: . . Implement and manage a network of alumni from U.S. government exchange programs to empower them to use their learned knowledge, skills, and perspectives to educate others and affect positive change in their communities.. . . . . ¬†. . . . . Program Objectives: . . The objectives of the USANT program are to: . . . . . 1.¬†¬†¬†¬†Increase engagement and communication between over 5,000 U.S. government exchange program alumni through a network.¬†. . . . . 2.¬†¬†¬†¬†Build career and leadership skills of alumni and their colleagues through professional development opportunities.. . . . . 3.¬†¬†¬†¬†Sustain continued interaction and communication between the U.S. Embassy and alumni.. . . . . 4.¬†¬†¬†¬†Increase the number of alumni-led projects focusing on sharing skills and knowledge gained during exchange programs.. . . . . 5.¬†¬†¬†¬†Recruit and partner with new and diverse alumni audiences to develop programs that support democratic values and economic reforms in Tajikistan. . . . . . ¬†. . . . . This funding opportunity seeks to provide continued logistical management of USANT to encourage networking among alumni and their colleagues and implement the Democracy Outreach Alumni Grant Program in fields that promote democratic values and economic reform in Tajikistan.¬†. . . . . ¬†. . . . . Participants and Audiences:. . . . . ¬?¬†¬†¬†¬†¬†¬†¬†The primary beneficiaries are alumni of U.S. government-sponsored exchange programs from across Tajikistan.¬†Alumni from all ages and level of expertise, who are highly motivated to create positive change in their communities. . . . . . ¬?¬†¬†¬†¬†¬†¬†¬†The sub-beneficiaries: Community leaders, youth, entrepreneurs, English teachers, women and girls, educators.. . . . . ¬†. . . . . Expected Activities to be managed by the implementing partner:. . . . . ¬?¬†¬†¬†¬†¬†¬†¬†. . Alumni Network of Tajikistan (USANT) ‚Äě $64,000. . . . . Continue to direct and manage a supportive network of alumni of U.S. government programs who will lead and participate in various training, educational, networking, and professional development activities throughout the year.. . . . . ¬†. . . . . ¬?¬†¬†¬†¬†¬†¬†¬†. . Regional Alumni Conferences, Trainings/Workshops -$16,000. . . . . Host conferences and collaborative workshops where alumni of U.S. government exchange programs can learn from each other, learn new skills, and learn ways to collaborate to increase the impact of their initiatives.¬†¬†. . . . . ¬†. . . . . ¬?¬†¬†¬†¬†¬†¬†¬†. . Democracy Outreach Alumni Small Grants - $120,000. . . . . Through the Democracy Outreach Alumni Small Grants program, USANT will support the U.S. Embassy in Dushanbe in the implementation of alumni initiatives that promote shared values and innovative solutions to global challenges. USANT will award a series of small grants to alumni, as well as partner with them to develop and carry out center programming.¬†These opportunities will build capacity of alumni to both manage small grants and implement a successful project, both important professional and life skills.¬†The intended long-term impact of the program is to encourage U.S. government alumni to take the initiative to strengthen local communities, foster positive relationships between the United States and Tajikistan, and promote mutual understanding of the core values promoted by U.S. government exchange programs, such as volunteerism, grassroots capacity building, and cooperation.. . . . . ¬†. . . . . The primary objectives of the Democracy Outreach Alumni Small Grants program are to: . . . . . 1.¬†¬†¬†¬†Strengthen civil society organizations‚Äô capacity through facilitating connections, relationships, and opportunities to collaborate. . . . . . 2.¬†¬†¬†¬†Strengthen local communities and the overall development of Tajikistan. . . . . . 3.¬†¬†¬†¬†Foster positive relationships between the people of the United States and Tajikistan. . . . . . 4.¬†¬†¬†¬†Promote American values such as volunteerism, community activism, tolerance, advocacy for vulnerable groups, and critical thinking. . . . . . 5.¬†¬†¬†¬†Strengthen the capacity of USG Alumni to use their exchange experience to address current challenges and issues in Tajikistan. . . . . . 6.¬†¬†¬†¬†Enhance connections between alumni of the various U.S. Government sponsored exchange programs in Tajikistan.. . . . . ¬†. . . . . USANT will disburse up to $120,000 in small grant awards over the course of the grant period. The small grant awards program will be administered in two rounds, in Fall 2023 and in Spring 2024 with calls for applications announced in September 2023 and March 2024. The amount of grants must not exceed $5,000 for organizations and $3,000 for individuals.¬†The U.S. Embassy is not setting a strict upper limit on grant amounts but advises that grants of $3,000 for individuals and $5,000 for organizations should be viewed as a rule-of-thumb limit.¬†

United States

NCCIH Multi-Site Feasibility Clinical Trials of Mind and Body Interventions (R01 Clinical Trial Required)

This Funding Opportunity Announcement (FOA) invites applications for investigator-initiated clinical trials of complementary and integrative health approaches with physical and/or psychological therapeutic inputs (often called mind and body interventions) in NCCIH-designated areas of high research priority. Applications submitted under this FOA are expected to propose a multi-site clinical trial to assess whether the intervention can be delivered with fidelity across sites; demonstrate feasibility of recruitment, accrual, and randomization of participants across sites; demonstrate participant adherence to the intervention, as well as retention of participants throughout the study across sites; and/or demonstrate feasibility of data collection across sites in preparation for a future multi-site trial. The need for multi-site feasibility trials are expected to be justified by sufficient preliminary data from previous single site feasibility or acceptability trial(s)or the published literature. This FOA will not support randomized clinical trials to determine efficacy or effectiveness. The data collected should be used to fill gaps in scientific knowledge necessary to develop a competitive fully powered multi-site clinical trial that has the potential to make a significant impact on public health Applicants are encouraged to contact the appropriate NCCIH Scientific/Research contact for the area of science for which they are planning to develop an application prior to submitting to this FOA..

United States

Rigorous Evaluation of Policies for their Impacts on the Primary Prevention of Multiple Forms of Violence

The Centers for Disease Control and Prevention (CDC), National Center for Injury Prevention and Control (NCIPC) is soliciting research proposals to expand the evidence base for policy approaches for the primary prevention of multiple forms of violence experienced by children, youth, and adults. Policies that promote the social and economic well-being of populations and address community characteristics associated with violence have the potential to not only reduce rates of multiple forms of violence, including the four forms that are the focus of this announcement: child abuse and neglect, youth violence/community violence, intimate partner violence (including teen dating violence), and sexual violence, but also impact health equity. To advance CDC’s commitment to achieving health equity, the intent is to support applications that investigate policies that address social and structural conditions to reduce the disproportionate burden of violence experienced by some groups and communities. Applications that empirically examine the health equity implications of selected policies on population(s) disproportionately impacted by violence are highly encouraged.

United States

Rigorous Evaluation of Policy-Level Interventions to Prevent Overdose (R01)

The Centers for Disease Control and Prevention’s (CDC) National Center for Injury Prevention and Control (NCIPC, Injury Center) is soliciting investigator-initiated research to rigorously evaluate effectiveness of policies for reducing drug use and overdose as well as the effect of these strategies on reducing or worsening existing disparities in medical care and health outcomes. Equally important to quantifying the impacts of these policies on health outcomes is understanding their implementation and how implementation affects achieving the intended outcomes of the policy among groups experiencing disproportionate burden of overdose and/or groups that are at greater risk of experiencing adverse outcomes related to substance use due to social determinants of health.The proposed research should evaluate the impact of a selected local, state, tribal, federal, or organizational policy (e.g., school or health systems) aimed at reducing or regulating substance use or reducing drug overdose, on rates of at least two overdose outcomes (i.e., nonfatal overdose, fatal overdose, substance use disorders, substance use, initiation of substance use among youth). 

United States

Sex Differences in Radiation Research: Models, Underlying Pathways, Biomarkers of Injury, and Medical Countermeasure Responses (U01 Clinical Trial Not Allowed)

The purpose of this Funding Opportunity Announcement (FOA) is to enable early-stage research to better understand the underlying causes of radiation-associated sex differences to advance radiation preclinical animal models, improve MCM development, increase the safety and efficacy of MCMs, and advance biomarker science to assess radiation injuries.

United States

NIDA Research Education Program for Clinical Researchers and Clinicians (R25 Clinical Trial Not Allowed)

The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this NIDA R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nations biomedical, behavioral and clinical research needs. This FOA is intended to support research education activities that enhance the knowledge of substance use and substance use disorder research. The program is intended for those in clinically focused careers and/or those training for careers as clinicians/health service providers, clinical researchers, or optimally a combination of the two. This mechanism may not be used to support non-research-related clinical training.

United States

Pilot and Feasibility Trials on the Integration of Social and Medical Care for Type 1 Diabetes Mellitus (R01 Clinical Trial Required)

The purpose of this NIDDK Funding Opportunity Announcement (FOA) is to support pilot and feasibility trials to test pragmatic interventions that include screening for adverse social determinants of health (SDoH) and referring or providing resource service linkages for social services within the healthcare setting for individuals living with type 1 diabetes. The pilot trials will determine 1) feasibility of screening for social risks and implementing referral service linkages (e.g., connecting persons in need to appropriate transportation, housing, food, etc. resources) within the context of a healthcare encounter, and 2) preliminary signals of the interventions impact on both the social risk(s) and type 1 diabetes (T1D) specific outcomes such as glycemic control. The overarching goal of this FOA is to stimulate collaborations between healthcare systems, community-based organizations, and social service entities for testing and advancing effective interventions which integrate social care and medical care to reduce health disparities in T1D.

United States

Innovation for HIV Vaccine Discovery (R01 Clinical Trial Not Allowed)

The purpose of this reissued Funding Opportunity Announcement (FOA) is to support high-risk, high-impact, early discovery research on vaccine approaches to prevent acquisition of or ongoing infection by HIV. In keeping with the high-risk, high-impact nature of this research, this FOA supports a Go/No-Go approach to funding high risk research, which is significantly different from most R01 projects. Continued funding for the full award duration is dependent upon achieving negotiated Go/No-Go criteria by the end of Year 2.

United States

Pilot Studies for the Spectrum of Alzheimers Disease/Alzheimers Disease-Related Dementias and Age-Related Cognitive Decline (R61 Clinical Trial Optional)

The purpose of this Funding Opportunity Announcement (FOA) is to 1) invite research grant applications that enable the collection of pilot data to support early stage testing of promising pharmacological and non-pharmacological interventions for cognitive and neuropsychiatric changes associated with age-related cognitive decline and Alzheimer's disease (AD) and Alzheimer's disease-related dementias (ADRD) across the spectrum from pre-symptomatic to more severe stages of disease, and 2) stimulate studies to enhance trial design and methods.

United States

Basket Clinical Trials of Drugs Targeting Shared Molecular Etiologies in Multiple Rare Diseases (U44 Clinical Trial Required)

The purpose of this Funding Opportunity Announcement (FOA) is to support basket clinical trials of drugs targeting shared molecular etiologies in more than one rare disease. To facilitate clinical trial start up, and leverage existing datasets, preference will be given to applications focusing on diseases that are under study by the Rare Disease Clinical Research Network (RDCRN), and that involve collaborations with RDCRN clinical investigators.

United States

Nechako-Kitamaat Development Fund Society

Up to 50% funding for community projects, infrastructure, arts, and economic development in NW BC

Grant Goals - Sustainable economic development - Community stability - Infrastructure improvement - Regional resilience - Social and cultural project support - Northern British Columbia community enhancement - Economic diversification - Local capacity building Keywords - Community development - Rural infrastructure - Northern BC grants - Economic revitalization - Social innovation - Community resilience - Regional funding - Grassroots support - Capacity building - Sustainable community projects - Local empowerment - Social enterprise - Community infrastructure - Economic diversification - Rural development - First Nations support - Community wellness - Social capital - Local economic strategies Description The Nechako-Kitamaat Development Fund Society provides targeted grants to support sustainable economic and community development in northwest British Columbia. Established in 1999 through joint funding from the Government of BC and Rio Tinto Alcan, the organization focuses on improving community infrastructure, social initiatives, and economic opportunities in the Nechako and Kitamaat regions. Target Audience - Non-profit organizations - Community groups - First Nations - Local governments - Regional societies - Community development initiatives - Social enterprises - Cultural organizations - Recreation associations - Municipal entities Eligible Expenses - Infrastructure projects - Community facility improvements - Recreation infrastructure - Cultural program development - Social service initiatives - Economic development projects - Trail and outdoor space creation - Community gathering space renovations - Equipment acquisition - Accessibility upgrades Eligibility - Located in Nechako-Kitamaat investment area - Registered non-profit or community organization - Projects supporting local economic or social development - Demonstrable community benefit - Alignment with regional development goals - Sustainable and impactful project design Program Requirements - Detailed project proposal - Clear community impact statement - Budget breakdown - Project timeline - Organizational capacity demonstration - Alignment with NKDF strategic objectives - Measurable outcomes - Community engagement evidence Hiring Criteria - Local talent prioritization - Community-based employment - Skills development focus - Inclusive hiring practices - Regional workforce engagement Due Dates - Four intake windows annually - January - March - July - October - Continuous intake for requests under $5,000 Start Dates - Flexible project commencement - Aligned with funding approval cycle - Typically within 6 months of grant approval Age Requirements - No specific age restrictions - Youth-led projects welcome - Intergenerational initiatives supported Industry / Area of Work - Community development - Social services - Cultural preservation - Recreation - Infrastructure - Economic diversification - First Nations support - Environmental sustainability - Arts and culture - Local economic initiatives

Kitamaat Village · Southside · Nee Tahi Buhn Band · Cheslatta Carrier Nation +10 more

OCI - Critical Industrial Technologies Initiative

75% funding for advanced tech in mining, manufacturing, agri-food, and construction.

Driving the commercialization and adoption of critical technologies to advance Ontario’s mining, advanced manufacturing, construction, and agri-food sectors.

Ontario

BioCreate Program

Up to 60% funding for genomics projects, mentorship, and infrastructure support.

BioCreate is a 5-year, $11.6 million program supported by the Government of Canada through the Federal Economic Development Agency for Southern Ontario (FedDev Ontario) and by Ontario Genomics. It provides funding, access to mentorship and business support to enable companies to raise additional financing to achieve commercial outcomes.

Ontario

Operating Grant: TRANSCAN-3

40% funding for health research, knowledge translation, and commercialization projects.

In the last decades the understanding of the molecular mechanisms responsible for cancer development and progression has significantly improved. In particular, a lot of progress has been made regarding the genetics of cancer that has led to the discovery and implementation into the clinic of numerous treatments as well as many biomarkers to improve screening, diagnosis and prognosis of cancers, leading to an increase in survival and improvement in the quality of life of cancer patients.. . Despite these significant advancements, there is still much to be learned about cancers research. More recently, epigenetics, the study of changes in gene expression without alterations in the DNA sequence, has emerged as an important area of investigation. The epigenetic research, driven by technological progress like high-throughput sequencing technology, has been developing rapidly. The improvement of knowledge of the chromatin structure and its accessibility along with the mechanisms of histone modifications has revealed the important role of epigenetic modifications in the gene expression. During development, the establishment of the epigenetic program is particularly important and its stability essential for the maintenance of the functions of each cell type. Alterations in epigenetic modifications are associated with several pathologies and have been particularly highlighted in cancers. It is commonly accepted now that cancers are as much epigenetic diseases as genetic ones. It remains to be understood to what extent these epigenetic alterations influence the development of a cancer and what their importance in tumour growth is.. . Epigenetic changes can be observed between healthy and cancerous cells. Large-scale cancer epi/genome sequencing efforts have currently revealed a very large number of epigenetic marks and genetic alterations in cancer cells and tissues. They may have clinical utility as potential tumour biomarkers to help identify specific cells and target the cell of origin of a given tumour or classify tumour type. Epigenetics thus represents an important tool for the improvement of early detection and the prediction of the disease. Epigenetics and epigenomics therefore have significant potential for clinical application as they can help clinicians diagnose certain types of tumours and could help determine the efficacy of treatments.. . The treatment targeting epigenetics is becoming an attractive and promising strategy for anticancer therapy. Indeed, unlike genetic alterations, which are irreversible, epigenetic modifications are reversible. This field of research thus offers great opportunity for new therapeutic approaches and has paved the way for the development of new therapeutic compounds, so-called epidrugs. Some new drugs directed at epigenetic modulators have already been developed and are available. However, apart from a few cases, the clinical applications of epidrugs, alone or in combination with radiotherapy, chemotherapy or immunotherapy, are still far from common practice, particularly for solid tumours. It is therefore necessary to translate the fundamental knowledge of this emerging field into concrete clinical applications.. . Considering this background, the TRANSCAN-3 partners have agreed to focus their third Joint Transnational Call for proposals (JTC 2023) on: "Translational research on cancer epigenetics". TRANSCAN-3 aims at promoting highly innovative and ambitious collaborative projects in translational cancer research at European and international level, and considers that, based on the previous grounds, it is timely and relevant to focus its funding on this topic.

Canada

Critical Minerals Infrastructure Fund – Indigenous Grants Program

100% funding for Indigenous engagement, capacity building, and knowledge sharing in critical minerals.

The Critical Minerals Infrastructure Fund (CMIF) supports the development and deployment of clean energy and transportation infrastructure that will enable the development and expansion of critical minerals projects in Canada. Indigenous engagement is a crucial part of this infrastructure and mining development, especially given that many proposed projects would take place on traditional Indigenous territories and treaty lands. The CMIF Grants program supports Indigenous engagement, knowledge sharing, and capacity building related to clean energy and transportation projects that would enable critical minerals development.

Canada

Catalyze: Enabling Technologies and Transformative Platforms for HLBS Research (R33 - Clinical Trials Not Allowed)

This Funding Opportunity Announcement (FOA) solicits grant applications to further develop enabling technologies and transformative platforms to catalyze next-generation predictive, diagnostic and therapeutic products to address heart, lung, blood, and sleep (HLBS)-related disorders and diseases. This FOA solicits R33 applications where major feasibility gaps for the enabling technology or transformative platform have already been overcome, as demonstrated with supportive preliminary data, but still requires further development and rigorous validation to encourage downstream demonstration, utilization and adoption. Well-suited applications must offer the potential to accelerate and/or transform the areas of early detection and screening, model development, clinical diagnosis, treatment, control, prevention or epidemiology, while addressing issues associated with HLBS-related diseases and disorders. Projects proposing application of existing technologies where the novelty resides in the biological or clinical target/question being pursued are not appropriate for this solicitation and will not be reviewed. This FOA is part of a suite of NHLBI Catalyze program to advance projects to the point where they can meet the entry criteria for the NHLBI Catalyze Product Definition or Preclinical FOAs.

United States

BRAIN Initiative: Transformative Brain Non-invasive Imaging Technology Development (UG3/UH3 Clinical Trial Not Allowed)

This Funding Opportunity Announcement (FOA) solicits applications for team-centric development and validation of innovative non-invasive imaging technologies that could have a transformative impact on the study of brain function/connectivity. Applications are expected to turn a novel concept into a functional prototype using this phased grant mechanism. The feasibility should be established by the end of its first phase and serve as a foundation for the transition to its second phase. Fully developing the technology into a functional prototype and validating it by in-vivo animal or human function/connectivity imaging are anticipated in the second phase. The research plan should provide a realistic timeline and tangible milestones to support the proposed development effort. Awards will be integrated into the BRAIN Non-Invasive Imaging Consortium, as a coordinated network on brain function/connectivity imaging.

United States

CABHI Ignite Program

Up to 150% funding for R&D, prototyping, testing, and validation of innovations.

The CABHI Ignite Program offers early-stage Canadian innovators funding between $50,000 to $150,000 CAD, along with acceleration services, to develop, test, and validate solutions aimed at improving the lives of older adults and those affected by dementia.

Canada

PARTENAR-IA – CQRDA – Industry

50% funding for AI projects, innovation, and collaboration in quantum technologies.

Get a non-refundable grant up to $150,000 per partner company (to a maximum of $600,000) to cover up to 50% of the expenses when you partner with at least one other business and a research centre on an artificial intelligence project that promotes the use of aluminium.

Quebec

OCI Collaborate 2 Commercialize (C2C)

50% funding for collaboration, R&D, and commercialization of innovative solutions.

A funding program that provides financial assistance to small and medium-sized enterprises (SMEs) in Ontario to help them adopt and implement innovative technologies or processes that will increase productivity and competitiveness.

Ontario

OCI - Technology Demonstration Program1

50% funding for digital adoption, training, and technology upgrades for Ontario SMEs.

The Technology Demonstration Program is designed to assist Ontario-based SMEs, particularly those with a completed DMAP project, in implementing the digital technologies outlined in their DMAP. It targets SMEs looking to drive growth through digital innovation, with eligibility criteria including a minimum annual revenue threshold.

Ontario

OCI - Technology Demonstration Program3

50% funding for digital adoption, training, and technology upgrades for Ontario SMEs.

The Technology Demonstration Program is designed to assist Ontario-based SMEs, particularly those with a completed DMAP project, in implementing the digital technologies outlined in their DMAP. It targets SMEs looking to drive growth through digital innovation, with eligibility criteria including a minimum annual revenue threshold.

Ontario

ICT Innovation Fund

up to 50% of innovation spend.

Encourages innovation in the ICT sector by providing funding for R&D and commercialization projects.

Canada

Cluster Building

Cluster Building Projects support groups of Canadian SMEs within industry-led, membership-based organizations to enhance capabilities through the application of, or access to advanced manufacturing technologies, best practices and principles.

Ontario

OCI - Technology Demonstration Program

50% funding for digital adoption plans, technology upgrades, and training for SMEs.

A government-funded program that provides funding to businesses in Ontario to support the development and adoption of advanced technologies.

Ontario

Sustainable Growth Investment – Growth Support Plus

70% funding for sustainable investments, covering interest costs and liquidity needs.

The Sustainable Growth Investment Program supports productive and sustainable investments for farmers, offering a grant of up to $150,000 alongside a loan guarantee of up to $600,000 from La Financičre agricole. Maximum eligible financing per business is $700,000, with assistance paid out over a three-year period.

Quebec